BDSX logo

BDSX Biodesix, Inc.

NASDAQ Global Market · Medical - Diagnostics & Research · Healthcare

$7.56
-0.74 (-8.92%)

Biodesix, Inc. is a data-driven diagnostic solutions provider operating across the United States. Its primary focus includes a comprehensive suite of blood-based lung tests, marketed as the Nodify Lung Nodule Risk Assessment (which includes Nodify XL2 and Nodify CDT). These assessments enable clinicians to evaluate the risk of lung cancer in patients with suspicious nodules, aiding in the reclassi…

Market Cap: $61.54Mwww.biodesix.com

Price

No data yet.

Social Signal Score

38
5d
0
1 mentions
—
30d
51
9 mentions
—
60d
49
15 mentions
—
90d
51
19 mentions
—
news: 19

Analyst Ratings

9 analysts
Buyconsensus
Strong Buy 0Buy 8Hold 1Sell 0Strong Sell 0
Avg price target$35+363.0%
Low $32Median $35High $38
Current Consensus

Revenue

$24.04M+370.65%
$3.94M$12.25M$20.56M$28.87M
Mar 2018Sep 2026

Analyst Estimates

FY2025
$-5.15
$-5.54–$-4.87
2 analysts
FY2026
$-2.95
$-3.13–$-2.68
5 analysts
FY2027
$-1.99
$-2.23–$-1.71
5 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Scott Hutton
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Employees
334
Beta
0.55
Country
US
Piotroski score
3 / 9 (Weak)
Altman Z-score
-6.53
www.biodesix.com